RxDoctor Payments DataLook up a doctor →

Thomas Blevins, MD

Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1114992088

Payments from drug & device makers

$7,434,636in general payments, 2019–2025

Across 2,589 payments — averaging $2871.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3M
  • Dexcom, Inc.$821K
  • AbbVie$712K
  • Boehringer Ingelheim$555K
  • Lilly USA, LLC$376K
  • Tandem Diabetes Care, Inc.$350K
  • plus $1.7M from 54 others
$212,067in research payments, 2019–2025

Across 284 payments — averaging $746.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$152K
  • Eli Lilly$55K
  • Mylan Inc.$6K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly108$2,969,182
Dexcom, Inc.58$821,294
AbbVie(2 entities)95$711,753
Boehringer Ingelheim137$554,735
Lilly USA, LLC579$376,254
Tandem Diabetes Care, Inc.29$350,060
Mannkind Corporation64$315,416
Novo Nordisk137$244,853
Sequel Med Tech, LLC184$205,108
Novo Nordisk AS548$191,234
Sanofi-aventis U.S. LLC95$120,464
BD3$118,900
Insulet Corporation23$94,011
Amgen(2 entities)42$92,057
Siemens Medical Solutions USA, Inc.16$66,080
AstraZeneca(2 entities)55$38,504
Boehringer Ingelheim International GmbH123$25,732
Amarin Pharma, Inc.31$20,926
Senseonics, Incorporated8$20,727
Medtronic(2 entities)70$15,260
Johnson & Johnson22$12,353
Regeneron Healthcare Solutions, Inc.25$11,968
Sanofi US Services Inc.5$11,066
Merck13$9,785
Mylan Specialty L.p.3$6,377
Zealand Pharma US, Inc.11$5,913
Abbott12$4,988
Esperion Therapeutics, Inc.6$4,326
Corcept Therapeutics11$3,985
Vistapharm, Inc.5$3,767
Convatec Inc.2$2,610
Xeris Pharmaceuticals, Inc.7$1,904
Bayer2$1,544
Antares Pharma, Inc.4$280
Radius Health, Inc.11$224
BETA Bionics, Inc.5$221
Novartis4$81
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$55
IBSA Pharma Inc.3$53
Kyowa Kirin, Inc.2$45
Aytu Biopharma, Inc.3$43
Recordati_rare_diseases_inc.2$41
Alvogen Inc2$35
Soleno Therapeutics, Inc.1$34
Nevro Corp.1$34
Chiesi USA, Inc.2$33
Genentech, Inc.1$33
Pfizer2$33
Intuity Medical Inc2$31
Amneal Pharmaceuticals LLC2$28
GSK1$26
Ascensia Diabetes Care US Inc.1$24
Valeritas, Inc.1$20
Halozyme Inc1$20
Cequr Corporation1$19
Ascendis Pharma Endocrinology Inc1$17
Acella Pharmaceuticals, LLC1$17
Shield Therapeutics Inc1$15
Lifescan, Inc.1$15
Tolmar, Inc.1$14

How this compares

$7,434,636 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$226,774
Medicare patients
838
Services billed
11,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Austin

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →